Signaling pathways
-
BA6351 OritinibSummary: SH-1028 is an irreversible third-generation that overcomes T790M-mediated resistance in non-small cell lung cancer. -
BA6352 PDZ1iSummary: PDZ1i is a potent, blood-brain barrier-crossing, specific inhibitor.
-
BA6353 EGFR-IN-70Summary: EGFR-IN-70 is a potent inhibitor.
-
BA6354 GW2974Summary: GW2974 is a potent dual inhibitor.
-
BA6356 PKI-166Summary: PKI-166 is a highly potent and selective, orally bioactive inhibitor.
-
BA6357 TheliatinibSummary: Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective inhibitor.
-
BA6359 DBPR112Summary: DBPR112 is an orally effective fluoropyrimidine-based inhibitor.
-
BA6360 SelatinibSummary: Selatinib is a reversible and orally active dual and inhibitor.
-
BA6361 PD-089828Summary: PD-089828 is an ATP-competitive inhibitor and a non-competitive inhibitor of tyrosine kinases.
-
BA6362 IzalontamabSummary: Izalontamab (SI-B001) is a bispecific anti-monoclonal antibody with high selectivity for EGFR/HER3 heterodimers.